The University of Osaka · Medicine
Professor Makoto Yamasaki's research lab focuses on the molecular mechanisms underlying cancer progression, particularly in esophageal and colorectal cancers. The lab investigates gene expression profiles and molecular markers—such as MRP2 and procarboxypeptidase A—associated with chemotherapy response and metastasis, aiming to improve treatment strategies for advanced and recurrent cancers. Their work spans from basic biochemical characterization to translational research, including clinical applications of chemotherapy regimens like DCF in esophageal squamous cell carcinoma (ESCC).
Figures are computed from collected data and may differ slightly.
Our data suggested that MRP2 is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in advanced ESCC patients.
DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTProcarboxypeptidase A-S6.* Further Studies of its Isolation and PropertiesMakoto Yamasaki, James R. Brown, David J. Cox, Roderick N. Greenshields, Roger D. Wade, and Hans NeurathCite this: Biochemistry 1963, 2, 4, 859–866Publication Date (Print):July 1, 1963Publication History Published online1 May 2002Published inissue 1 July 1963https://pubs.acs.org/doi/10.1021/bi00904a039https://doi.org/10.1021/bi00904a039research-articleACS PublicationsRequest reus
The major cause of death in colorectal cancer is related to liver metastasis. Although the metastatic process has been well studied, many aspects of the molecular genetic basis of metastasis remain unclear. Elucidation of the molecular nature of liver metastasis is urgent to improve the outcome of colorectal cancer. We analyzed the chronological gene expression profiles of 104 colorectal samples corresponding to oncogenic development including normal mucosa, localized and metastasized primary tu
The LN response to NACT predicted long-term survival more precisely than the PT response in patients with metastatic EC.
Open papers in the app to read, cite, and organize with AI.
